DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
This is a quick episode to describe what to expect from the Innovation4Alpha podcast hosted by Tobin Arthur.
Dr. Krell is a fascinating general dentist with a combined business background. He is currently the Head of Marketing at Simplifeye, based in NYC,...
Amir Baluch, MD, is an investor, serial entrepreneur, and fund manager at BioWise Capital. Dr. Baluch has ten years experience in private equity and...
